VALSARTAN HYDROCHLOROTHIAZIDE ZENTIVA LAB 160 mg/25 mg, film-coated tablet 30 tablets
Active ingredients: HYDROCHLOROTHIAZIDE, Valsartan
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VALSARTAN HYDROCHLOROTHIAZIDE ZENTIVA LAB 160 mg/25 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s)
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 21 Oct 2011
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60560046CIP73992249CIP133400939922492Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| HYDROCHLOROTHIAZIDEcomprimé | 25 mg · un comprimé | SA |
| VALSARTANcomprimé | 160 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.